Editas Medicine (EDIT) Reports Q4 Loss of $0.52/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
February 28, 2019 4:01 PM ESTEDIT-101 for LCA10 set to be first ever in vivo CRISPR medicine administered to patients with dosing expected in second half of 2019
Advancing potentially best-in-class engineered cell medicine for
sickle cell disease and beta-thalassemia
Appointed Cynthia Collins and David Scadden, M.D., to Board of Directors
and named Collins as interim Chief Executive Officer
Year-end cash, cash equivalents, and marketable securities of $369 million expected to fund advancement of multiple transformative experimental medicines
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) --... More
